Table 4.

AChE/BuChE inhibitory activities and oxygen radical absorbance capacity (ORAC, Trolox equivalents) by target compounds 5a–5j, 7a–7l, 10a–10v and the positive compounds naringenin, apigenin, genistein and rivastigmine.

Compound	ORACa	IC50 ± SDb (μM)		SIe	IC50 ± SDb (μM)		SIe
		ratAChEc	ratBChEd		huAChEf	huBuChEg
5a	2.2 ± 0.03	6.7 ± 0.31	20.9 ± 0.68	3.1	NTh	NTh	–
5b	2.1 ± 0.04	5.8 ± 0.19	17.4 ± 0.52	3.0	NTh	NTh	–
5c	2.3 ± 0.02	3.9 ± 0.44	22.6 ± 0.23	5.8	NTh	NTh	–
5d	2.2 ± 0.02	2.0 ± 0.46	18.1 ± 0.56	9.1	NTh	NTh	–
5e	2.5 ± 0.01	9.2 ± 0.72	13.2 ± 0.43	1.4	NTh	NTh	–
5f	2.3 ± 0.03	1.7 ± 0.08	16.9 ± 0.27	9.9	0.91 ± 0.02	6.3 ± 0.74	6.9
5g	2.1 ± 0.02	2.5 ± 0.33	18.7 ± 0.33	7.5	NTh	NTh	–
5h	2.3 ± 0.03	3.3 ± 0.09	15.5 ± 0.52	4.7	NTh	NTh	–
5i	2.1 ± 0.04	4.9 ± 0.16	14.7 ± 0.62	3.0	NTh	NTh	–
5j	2.2 ± 0.05	6.5 ± 0.09	15.9 ± 0.37	2.9	NTh	NTh	–
7a	1.1 ± 0.02	10.1 ± 0.41	20.2 ± 0.23	2.0	NTh	NTh	–
7b	1.2 ± 0.04	7.4 ± 0.29	18.7 ± 0.37	2.5	NTh	NTh	–
7c	1.2 ± 0.02	6.7 ± 0.16	19.4 ± 0.28	2.9	NTh	NTh	–
7d	1.0 ± 0.03	9.3 ± 0.37	20.3 ± 0.26	2.2	NTh	NTh	–
7e	1.5 ± 0.02	8.2 ± 0.47	15.8 ± 0.62	1.9	NTh	NTh	–
7f	1.1 ± 0.03	5.4 ± 0.16	20.7 ± 0.55	3.8	NTh	NTh	–
7g	1.2 ± 0.04	1.4 ± 0.08	15.7 ± 0.29	11.2	NTh	NTh	–
7h	1.0 ± 0.04	0.86 ± 0.05	16.9 ± 0.34	19.7	NTh	NTh	–
7i	1.4 ± 0.03	6.1 ± 0.21	12.3 ± 0.16	2.0	NTh	NTh	–
7j	1.1 ± 0.03	1.4 ± 0.08	15.7 ± 0.29	11.2	NTh	NTh	–
7k	1.2 ± 0.02	0.79 ± 0.06	14.8 ± 0.36	18.7	0.57 ± 0.02	8.2 ± 0.37	14.4
7l	1.2 ± 0.01	2.2 ± 0.13	15.1 ± 0.28	6.9	NTh	NTh	–
10a	1.1 ± 0.01	8.1 ± 0.27	16.8 ± 0.36	2.1	NTh	NTh	–
10b	1.0 ± 0.04	4.3 ± 0.38	18.6 ± 0.24	4.3	NTh	NTh	–
10c	1.2 ± 0.03	5.5 ± 0.17	13.6 ± 0.67	2.5	NTh	NTh	–
10d	1.1 ± 0.02	6.4 ± 0.22	15.1 ± 0.49	2.4	NTh	NTh	–
10e	1.1 ± 0.02	7.9 ± 0.26	13.8 ± 0.43	2.3	NTh	NTh	–
10f	1.0 ± 0.04	8.6 ± 0.33	16.7 ± 0.52	1.9	NTh	NTh	–
10g	1.2 ± 0.03	4.6 ± 0.21	17.4 ± 0.35	3.8	NTh	NTh	–
10h	1.1 ± 0.03	0.92 ± 0.06	12.9 ± 0.51	14.0	0.16 ± 0.01	3.7 ± 0.06	23.1
10i	1.5 ± 0.02	6.9 ± 0.14	10.3 ± 0.19	1.7	NTh	NTh	–
10j	1.2 ± 0.03	1.8 ± 0.04	15.7 ± 0.24	8.7	NTh	NTh	–
10k	1.1 ± 0.02	0.81 ± 0.05	13.3 ± 0.27	16.4	0.13 ± 0.01	4.5 ± 0.12	34.6
10l	1.3 ± 0.03	0.62 ± 0.05	14.4 ± 0.32	23.2	0.09 ± 0.002	2.2 ± 0.18	24.4
10m	1.2 ± 0.02	1.3 ± 0.08	16.6 ± 0.27	12.8	NTh	NTh	–
10n	1.1 ± 0.04	3.6 ± 0.11	17.9 ± 0.46	4.9	NTh	NTh	–
10o	1.2 ± 0.03	4.1 ± 0.63	16.1 ± 0.25	3.9	NTh	NTh	–
10p	1.1 ± 0.02	6.2 ± 0.54	13.8 ± 0.37	2.2	NTh	NTh	–
10q	1.0 ± 0.02	4.2 ± 0.15	12.2 ± 0.28	2.9	NTh	NTh	–
10r	1.2 ± 0.04	1.7 ± 0.21	14.1 ± 0.22	8.3	NTh	NTh	–
10s	1.1 ± 0.03	2.6 ± 0.33	16.9 ± 0.54	6.5	NTh	NTh	–
10t	1.0 ± 0.02	5.9 ± 0.37	19.3 ± 0.67	3.3	NTh	NTh	–
10u	1.2 ± 0.03	6.3 ± 0.21	17.2 ± 0.45	2.7	NTh	NTh	–
10v	1.3 ± 0.03	8.1 ± 0.49	14.8 ± 0.29	1.8	NTh	NTh	–
naringenin	5.2 ± 0.29	>50	>50	–	NTh	NTh	–
apigenin	5.6 ± 0.52	>50	>50	–	NTh	NTh	–
donepezil	NTh	0.017 ± 0.003	16.2 ± 0.31	953	0.013 ± 0.0004	2.7 ± 0.06	208

^aResults are expressed as μM of Trolox equivalent/μM of tested compound. ^bValues are expressed as the mean ± standard deviation of the mean by 3 independent experiments in triplicate. ^cFrom 5% rat cortex homogenate. ^dBuChE from rat serum. ^eSelectivity Index = IC₅₀ (BuChE)/IC₅₀ (AChE). ^fFrom human erythrocytes. ^gFrom human serum. ^hNT = not tested.